RAC1 and prostate cancer: These results suggest that Rac1 and Cdc42 hyperactivation in androgen-independent prostate cancer cells does not involve aberrant upstream signaling mediated by PI3K/Gβγ -dependent exchange factors, such as P-Rex1.